Trial Profile
Phase I Study of Recombinant Interleukin 15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects With Refractory Cancers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Interleukin-15 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cervical cancer; Cholangiocarcinoma; Colon cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- 13 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.